Further, we have shown that by pharmacologically inhibiting CCR2 we could block cell migration to Hp, further strengthening the notion that drugs for the obesity-induced inflammatory state could be developed by acting on this receptor. The gene discussed is HP; the disease is obesity due to melanocortin 4 receptor deficiency.